Evaluation of QT interval duration and dispersion and proposed clinical criteria in diagnosis of long QT syndrome in patients with a genetically uniform type of LQT1  by Swan, Heikki et al.
Evaluation of QT Interval Duration and Dispersion and Proposed
Clinical Criteria in Diagnosis of Long QT Syndrome in Patients With
a Genetically Uniform Type of LQT1
HEIKKI SWAN, MD, KIRSI SAARINEN, MSC, KIMMO KONTULA, MD, LAURI TOIVONEN, MD,
MATTI VIITASALO, MD
Helsinki, Finland
Objectives. This study investigated the ability of QT duration,
QT dispersion (QTD) and clinical diagnostic criteria to correctly
identify genetically documented LQT1 type long QT syndrome
(LQTS) patients, and to separate symptomatic and asymptomatic
LQT1 patients.
Background. Ventricular repolarization has played an essential
role both in diagnosis and risk assessment of LQTS. Today,
molecular genetic techniques permit unequivocal identification of
many LQTS patients.
Methods. QT interval and QTD in 12 symptomatic and 18
asymptomatic LQT1 patients and their 43 healthy relatives were
evaluated. The sensitivity and specificity of upper normal limits of
QT interval, two QT interval adjustment methods (Bazett’s and
Fridericia’s formulas), and the proposed clinical criteria for
LQTS were assessed. Occurrence of a mutant (D188N) KVLQT1
gene was considered as the basis of classification into affected and
nonaffected individuals.
Results. Diagnostic sensitivity and specificity values were 90%
and 88% using Bazett’s formula, and 80% and 100% using
Fridericia’s cubic root formula or upper normal limits for QT
interval. Suggested diagnostic criteria for LQTS reached 100%
specificity, but 47% of the DNA-documented LQT1 patients were
classified into the category of low or intermediate probability of
LQTS. QT interval and heart rate did not differ between symp-
tomatic (464 6 47 ms, 70 6 9 min21) and asymptomatic 460 6
41 ms, 65 6 13 min21) LQT1 patients. QTD was increased in
symptomatic LQT1 patients compared to unaffected relatives
(66 6 48 vs. 37 6 15 ms, p 5 0.02), but symptomatic patients
LQT1 did not differ from asymptomatic (45 6 19 ms).
Conclusions. Not all LQT1 patients can be distinguished from
healthy relatives by assessment of QT duration or clinical criteria.
Presence of LQT1 gene can carry the risk of cardiac events even
with no or only marginal prolongation of QT interval.
(J Am Coll Cardiol 1998;32:486–91)
©1998 by the American College of Cardiology
Congenital long QT syndrome (LQTS) is most often inherited
in an autosomal dominant trait and is associated with malig-
nant arrhythmias (1–3). The diagnosis is usually based on
prolongation of ventricular repolarization time but linkage
studies have shown that QT interval duration alone may not be
sufficient for correct diagnosis (4,5). Therefore, additional
diagnostic criteria have been proposed to classify the border-
line cases (6,7). One of the confounding factors leading to
misdiagnosis may be the heart rate correction of QT interval.
Indeed, the adequacy of the most widely used formula to adjust
the QT interval for heart rate has been questioned (8–10).
Theoretically, the drawbacks of QT adjustment may also have
caused a selection bias in studies carried out among LQTS
patients since the inclusion criteria in various studies have
usually been based on the QT interval alone or combined with
other diagnostic criteria.
Identification of both symptomatic LQTS patients as well as
their asymptomatic affected relatives is important as they are
known to be at increased risk of cardiac events (11–13). The
risk of events in LQTS, including syncope or sudden death, has
been related to the extent of QT interval duration (14). In
addition to prolonged QT interval, QT dispersion, a measure
of repolarization inhomogeneity (15), is one of the parameters
that can be measured from surface electrocardiogram (ECG)
and might serve as an indicator of increased risk of arrhythmic
events (15). In addition, QT dispersion has been suggested to
be a predictor of therapeutic efficacy in LQTS (16). However,
as LQTS is a genetically heterogeneous disorder with multiple
ion channel pathologies (17–20), the utility of the risk markers
may vary in different subtypes of LQTS.
Identification of the disease-causing mutation of the cardiac
potassium channel gene KVLQT1 in a very large family (5) has
now permitted us to compare the repolarization parameters in
DNA-documented carriers of the mutation and their healthy
relatives. First, as the diagnosis of LQTS was based on
molecular genetic analysis and not on QT interval measure-
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ments, we compared the distribution of QT intervals in LQT1
patients to those in healthy relatives and to population-based
normal upper limits. Second, we assessed the sensitivity and
specificity of the commonly used normal upper limit of QT
interval (440 ms), together with different correction algorithms
as well as the proposed clinical diagnostic criteria (6) in
identifying carriers of the mutation. Third, we examined
whether the duration of QT interval or increased dispersion of
QT could distinguish symptomatic from asymptomatic patients
within this genetically defined population.
Patients and Methods
The study group consisted of members of a family in which
a large number of individuals were identified to be carriers of
a mutant KVLQT1 gene causing LQTS type 1 (LQT1).
Identification of the mutation and the pedigree has been
presented earlier (5). In brief, the proband of the family was a
10-year old girl who was subjected to cardiologic examinations
because of a syncope upon running. In addition to the proband
and her mother, 28 relatives were found to be carriers of a
substitution of asparagine for aspartic acid at codon 188 of the
KVLQT1 gene (5). This mutation (D188N) is localized to the
pore-S6 region of the KVLQT1 channel, substitutes a con-
served amino acid residue and destroys an existing BsmFI
restriction site in the KVLQT1 gene, thus permitting its
convenient analysis by polymerase chain reaction (PCR) fol-
lowed by restriction enzyme digestion (5). The physicochemi-
cal nature of the mutation, its cosegregation with the LQTS
phenotype in the index family and its absence in a large
number of random controls provide convincing evidence for its
disease-causing role (5).
Twelve of the patients in LQT1 group had experienced an
exercise-related syncope. The youngest symptomatic patient
was 3 years old at the time of the first syncope. Eight patients
had experienced syncope at the age of 5 to 25 years and 3
patients between 30 to 37 years. In addition to them, one boy
was drowned at the age of 10. Although not studied for DNA,
he was included in the study group since his QTc was 450 ms,
he had been treated for LQTS because of multiple exercise-
related syncopal attacks before his death and his mother is a
carrier of the D188N mutation.
As a control group, we studied 44 noncarriers of the
mutation from the same pedigree. One diabetic subject was
excluded from the study because diabetes mellitus may affect
the repolarization time (21). Seven LQT1 patients (5 symp-
tomatic, 2 asymptomatic) and one control subject were receiv-
ing beta-adrenergic blocking agents during the time of ECG
registration. In two cases (both LQT1 patients) beta-
adrenergic antagonists had been discontinued for at least five
half-lives before ECG was obtained. No other medications
known to affect the repolarization were in use. Clinical char-
acteristics of the LQT1 patients and controls are summarized
in Table 1. The study was approved by the institutional review
committee and was in accordance with the institutional guide-
lines. An informed consent was obtained from all patients and
controls.
ECG analysis. All patients and controls had standard
12-lead electrocardiogram (ECG) recorded at paper speed
50 mms21 and amplification of 0.1 mV/mm. ECG measure-
ments were carried out by one investigator who was unaware of
the genotypes of subjects. All subjects were in sinus rhythm,
and no one had atrioventricular or bundle branch block. Heart
rate was calculated from the three RR intervals preceding the
measured QT intervals. QT intervals were measured manually
from the onset of the QRS complexes to the end of T wave
defined as the intersection of isoelectric line and the tangent of
maximal downward limb of the T wave (22). The early phase of
repolarization (QTm) was measured from the onset of QRS
complex to the apex of T wave in each lead. In cases with
notched or double peaked T wave, the first peak was chosen
for QTm measurement. Each registered measurement was a
mean of two consecutive QT intervals in each lead. If the
amplitude of T wave was low (,0.1 mV), the lead was excluded
from the analysis.
QT dispersion (QTD) was defined as the difference be-
tween the maximal and minimal QT interval in any of the leads
measured. Relative QT dispersion (rQTD) was calculated as
follows: (the SD of QT/mean QT) 3 100. Relative QTm
dispersion (QTmD) was defined as (the SD of QTm/mean
QTm) 3 100.
At least 9 leads were available for measurements in each
Abbreviations and Acronyms
DNA 5 Deoxyribonucleic acid
ECG 5 Electrocardiogram, electrocardiographic
LQTS 5 Long QT syndrome
LQT1 5 LQT1 type of long QT syndrome
QTc 5 QT interval corrected with the square root formula
(QT/RR1/2)
QTD 5 QT dispersion
QTfc 5 QT interval corrected with the cubic root formula (QT/
RR1/3)
QTm 5 QT interval measured from QRS onset to T wave peak
rQTD 5 Relative QT dispersion
Table 1. Clinical and Electrocardiographic Characteristics of LQT1
Patients and Controls
LQT1 Controls
p
Value
Number of subjects 30 43
Mean age (years) 36 6 19 44 6 20 NS
Age range (years) 11–69 7–72
Men/women 10/20 22/21 NS
Resting heart rate min21
Without betablockers 68 6 12 (n 5 23) 68 6 12 (n 5 41) NS
On betablocker therapy 64 6 9 (n 5 7) 78 (n 5 1)
QT interval (ms) (lead II) 461 6 41 381 6 33 ,0.001
QTc interval (ms) (lead II) 484 6 38 404 6 25 ,0.001
NS 5 not significant, QTc 5 QT/RR
1/2 (23).
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subject. QT interval was adjusted for subject’s heart rate using
Bazett’s formula (QTc 5 QT/RR
1/2 (sec) (23). In order to
compare the sensitivity and specificity of different methods to
adjust for heart rate in separating LQT1 patients from their
healthy relatives, we also calculated corrected QT intervals
(QTfc) adjusted for heart rate by the Fridericia’s cubic root
formula (QTfc 5 QT/RR
1/3) (24). In addition to these adjust-
ment methods, unadjusted QT values were also compared to
upper normal limits for both genders. As the upper reference
limit, we used the mean plus 1.96 standard deviation (SD)
estimated at specific heart rates in a large survey of 10717
middle-aged Finnish subjects (25). Measurements from lead II
were used for comparisons between these normal values and
different heart rate corrected QT intervals.
Application of proposed clinical criteria. We also divided
patients into three probability groups according to the pro-
posed clinical criteria for diagnosing LQTS (6). These criteria
take into account the ECG findings, clinical history and family
history. QTc values equal to or exceeding 480 ms
1/2 are
assigned a value of 3 points and QTc 460–470 ms
1/2 2 points
(for males, even QTc 450 ms
1/2 1 point); torsades de pointes or
stress-related syncope 2 points (syncope without stress 1
point), T-wave alternans and/or notched T wave in three leads
1 point each, and for children, resting heart rate lower than the
second percentile for age 0.5 point. Congenital deafness in-
creases the score by 0.5 point, sudden cardiac death before the
age of 30 years among immediate family members by 0.5 point
or presence of family members with definite LQTS (score $ 4),
by 1 point. According to the proposed criteria, patients receiv-
ing 0 to 1 points have low, those with 2 to 3 points intermedi-
ate, and individuals receiving 4 or more points, high probability
of LQTS.
Statistical analysis. Data are presented as mean 6 1 SD.
Comparisons between two groups were performed by two-
tailed Student t test for unequal or equal variances where
appropriate, and differences among symptomatic and asymp-
tomatic LQT1 patients and controls were assessed by one-way
analysis of variance and by Scheffe’s test, or Mann-Whitney
U-test if the between-groups variances differed significantly.
For dichotomous variables chi-square test was used. The
correlation between QT and QT dispersion indexes was eval-
uated using linear regression analysis. A p value of ,0.05 was
considered as significant.
Results
QT interval measurements. Demographic and electrocar-
diographic characteristics of all 30 LQT1 patients and controls
are summarized in Table 1. No gender-related differences were
seen in resting heart rates (patients with beta blocking medi-
cation excluded), or mean, maximal or minimal QT intervals
among the LQT1 patients or within control group. Figure 1
shows the actual QT intervals in relation to heart rates in both
study groups. The mean of all QT interval estimates were
longer among LQT1 patients, whether symptomatic or asymp-
tomatic than in controls (Table 2). All the parameters pre-
sented in Table 2 were reevaluated after exclusion of patients
with beta blocking medication, and differences between the
patients and controls remained. Both actual and rate-adjusted
QT interval parameters presented (Table 2) as well as QTm
values were similar in symptomatic and asymptomatic LQT1
patients. There was some overlapping of the individual QTc
and QTfc values between symptomatic and asymptomatic
LQT1 patients and controls (Fig. 2). Frequency of symptom-
atic patients in the subset of LQT1 patients with QTc .476 ms
(median of all affected individuals) did not differ significantly
from those with QTc ,476 ms.
Dispersion of repolarization. Dispersion of QT in symp-
tomatic LQT1 patients was increased (66 6 48 ms) compared
to controls (45 6 19 ms, p 5 0.02). The mean value for
dispersion of QT in the asymptomatic LQT1 patients did not
Figure 1. Distribution of QT intervals according to heart rate. Provi-
sional normal upper limits for QT interval derived from a study on
population (25) are marked for men (solid line) and for women
(dashed line).
E controls, men
Q LQT1, men, symptom 2
F LQT1, men, symptom 1
 controls, women
1 LQT1, women, symptom 2
 LQT1, women, symptom 1
Table 2. Total and Early Duration of Repolarization and Heart
Rate Corrected QT Intervals in Symptomatic and Asymptomatic
LQT1 Patients and Controls
Symptomatic
LQT1
(n 5 12)
Asymptomatic
LQT1
(n 5 18)
Controls
(n 5 43) p Value
HR (beats/min) 70 6 9 65 6 13 69 6 12 NS
QT (lead II) 464 6 47 459 6 38 381 6 33 ,0.001*
QTmean 472 6 46 460 6 41 379 6 33 ,0.001*
QTmin 439 6 44 434 6 42 358 6 32 ,0.001*
QTmax 506 6 66 479 6 47 395 6 37 ,0.001*
QTc (lead II) 496 6 38 475 6 36 404 6 25 ,0.001*
QTfc (lead II) 485 6 38 469 6 31 396 6 22 ,0.001*
QTm (lead II) 391 6 44 380 6 33 310 6 32 ,0.001*
HR 5 heart rate, QT 5 measured QT interval. QTmin, QTmean, QTmax 5
minimal, mean and maximal QT interval measured from 12-lead ECG. QTc 5
QT/RR1/2, QTfc 5 QT/RR
1/3, QTm 5 early duration of repolarization, * 5
symptomatic LQT1 patients vs. controls, and asymptomatic LQT1 patients vs.
controls.
488 SWAN ET AL. JACC Vol. 32, No. 2
QT INTERVAL, DISPERSION AND CLINICAL CRITERIA IN LQT1 August 1998:486–91
differ significantly from that in the symptomatic or in the
control individuals (Fig. 3). QT dispersion and mean QT did
not correlate significantly with each other in LQT1 patients
(r 5 0.34, p 5 0.07) or controls (r 5 0.28, p 5 0.64).
Relationship between QT dispersion and mean QT is shown in
Figure 4. Dispersion of early phase of repolarization (QTm)
was increased in the group of symptomatic LQT1 patients
(57 6 32 ms) compared to controls (32 6 15 ms, p 5 0.006),
whereas asymptomatic patients and control individuals did not
differ significantly in this respect (Fig. 3). Relative dispersion
of early phase of repolarization (rQTm) did not differ signifi-
cantly between any of the three groups, however (Fig. 3). After
exclusion of patients with beta blocking medication, the rela-
tive dispersion of early phase of repolarization differed signif-
icantly between symptomatic LQT1 patients and controls
(5.2 6 2.9 versus 3.3 6 1.4, p 5 0.02).
Performance of QT measures and proposed clinical diag-
nostic criteria in revealing the genotype. We evaluated the
sensitivity and specificity of two different QT adjustment
formulas (23,24) to correctly diagnose the carriers of the
KVLQT1 mutation. QT intervals adjusted for heart rate
according to Bazett’s square root formula or Fridericia’s cubic
root formula exceeding 440 ms were considered abnormal.
Second, the sensitivity and specificity of the provisional normal
upper limits for QT interval obtained in a large Finnish
population survey were assessed. Third, the application of
proposed diagnostic criteria for LQTS (6) in the present
KVLQT1 population was tested. The distribution of QT
intervals at different heart rates according to genotype and
gender is shown in Figure 1. The division of gene carriers and
noncarriers into affected and nonaffected according to QT
interval adjustment methods, normal values or diagnostic
criteria are presented in Table 3. Diagnostic sensitivity and
specificity based on Bazett’s formula were 90% and 88%,
respectively, while assessment by heart rate-adjusted QT inter-
vals according to the Fridericia’s cubic root formula yielded
sensitivity of 80% and specificity of 100%. Classification ac-
cording to the normal upper limit (mean 6 2 SD) of QT
interval obtained from a large population study (25) resulted in
a sensitivity of 80% and specificity of 100%. Application of the
renewed diagnostic criteria for LQTS (6) to our study popu-
lation reached 100% specificity, but of the affected, 27% were
classified into the category of low probability, 20% into cate-
gory of intermediate probability and only 53% to the category
of high probability of LQTS.
Figure 2. QT intervals adjusted according to Bazzet’s formula (QTc)
(23) and Fridericia’s cubic root formula (QTfc) (24) for symptomatic
and asymptomatic LQT1 patients and controls.
n QTc
h QTfc
Figure 3. Mean dispersion values for total duration of ventricular
repolarization (QT dispersion, upper left panel), early duration of
ventricular repolarization (QTm dispersion, lower left panel) and
corresponding relative QT and QTm dispersions (upper right and
lower right panels, respectively) for symptomatic and asymptomatic
LQT1 patients and controls. SEM indicated above the bars.
Figure 4. Relation of QT dispersion and heart rate.
n LQT1 symptomatic
h LQT1 asymptomatic
3 Controls
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Discussion
Our results show that overlapping of QT interval durations
occurs between LQTS patients and normal population, irre-
spective of method used to judge QT interval normality. Thus,
a standard 12-lead ECG is an insufficient method to diagnose
all affected LQTS patients, even in a genetically homogenous
population. There is an urgent need for accurate methods that
would minimize the number of borderline cases when suspect-
ing LQTS.
QT duration. In this study the duration of ventricular
repolarization in symptomatic and asymptomatic LQT1 pa-
tients with the same genotype was similar. This is a disquieting
finding but may only seemingly contrast the prevailing view of
the predictive importance of length of QT interval as such.
Previous large family studies (3) and investigations in children
with LQTS (14) have shown that the longer the duration of
ventricular repolarization, the higher the risk of cardiac events.
In the former study, the family members with QTc #440 ms
were defined as unaffected and their risk of cardiac events
proved too low (3); however, in lack of molecular diagnosis of
LQTS this study (3) does not tell the exact risk of malignant
arrhythmias of LQTS gene carriers with QTc ,440 ms. More-
over, it is likely that in both studies cited above (3,14)
individual families have been heterogeneous in terms of the
causative genes and mutations. Since certain families have
shown to have had a more malignant course than on the
average (26), it is possible that certain LQTS mutations are
more virulent than others. This does not necessarily imply that
a family member with a specific mutation and a marginally
prolonged QT interval in standard 12-lead ECG has a lower
risk than a relative whose QT prolongation is more substantial
because a carrier status of a specific mutation itself seems to be
the major determinant of cardiac events.
QT dispersion. We found that the dispersion of ventricular
repolarization was increased in symptomatic LQTS patients.
Increased dispersion of the QT interval in patients with LQTS
has been reported in several earlier studies without performing
molecular diagnosis (16,27,28). However, conclusions on the
relationship between degree of dispersion and risk of cardiac
events have been inconsistent. The study by Linker et al. (28)
showed no difference in the degree of dispersion between
LQTS groups with frequent or infrequent symptoms whereas
Priori et al. found that LQTS patients who responded to
beta-blockade had lower QT dispersion than nonresponders
while on beta-adrenergic antagonists therapy (16). In our
molecularly defined cohort of LQTS patients, overlapping of
QT dispersion between groups was considerable (Fig. 4) and
accordingly in the individual risk assessment the value of QT
dispersion appears to be low.
Clinical diagnostic criteria of LQTS. The present study
shows that the proposed diagnostic criteria of LQTS (6) used
for clinical and research purposes among patients with un-
known genotype are conservative in classifying members of the
LQTS families. In clinical practice, the diagnostic criteria are
always a compromise, between trying to treat those at real risk
and avoiding unnecessary treatments of those without signifi-
cant risk. For research purposes, various ECG and/or clinical
criteria have been applied as inclusion criteria to define the
presence or absence of LQTS. These criteria have typically
included the duration of QTc, with the diagnostic criteria
proposed by Schwartz et al. (6) receiving highest acceptance.
Our data on a genetically homogenous population of LQT1
patients suggest that application of these criteria, including
those of Schwartz et al. (6), to patient selection results in true
positive diagnosis with a high probability of correctness; but a
considerable proportion of the affected patients will be ex-
cluded. It is therefore possible that in many previous clinical
studies on LQTS, based on the available diagnostic criteria, a
number of affected subjects remained undiagnosed, and con-
clusions on clinical outcome were drawn from the most
aberrant patients and their responses.
Clinical implications. Despite the improvement in diag-
nostic accuracy due to molecular genetics, the question of need
to treat asymptomatic gene carriers remains open. It is of note
that a total of 6 (20%)—two symptomatic and four asymptom-
atic—LQT1 patients had QT interval at or below the upper
limit of normal population. Although their QT interval is still
“normal,” it can be speculated that the duration of repolariza-
tion in these individuals would be even shorter without the
KVLQT1 gene mutation. Previously, when genetic diagnosis
was not available, it was recommended that asymptomatic
children with family history of LQTS and QTc .440 ms, that is,
those who were potential asymptomatic carriers of the LQTS
gene, should be treated. We believe today, however, that risk
assessment and decision to treat should be based on genetic
analysis, if feasible, and on additional risk factors. For instance,
increasing age and male gender appeared to associate with a
more favorable outcome in the study of Zareba et al. (13). On
the other hand, long QT interval may predict cardiac events,
but its role must now be reevaluated using reference QT values
for the particular population, together with other risk factors in
larger genetically defined populations. Increased QT disper-
Table 3. Application of Various Diagnostic Alternatives in LQTS in
Regard to Molecular Classification of Patients and Their Relatives
Diagnostic Classification
Genetic Status
D188N 1 D188N 2
Bazett (23)
QTc ,440 ms 3 38
QTc .440 ms 27 5
Fridericia (24)
QTfc ,440 ms 6 43
QTfc .440 ms 24 0
Population study (25)
QT , upper normal limit 6 43
QT . upper normal limit 24 0
Proposed diagnostic criteria for
the LQTS (6)
Low probability 8 43
Intermediate probability 6 0
High probability 16 0
490 SWAN ET AL. JACC Vol. 32, No. 2
QT INTERVAL, DISPERSION AND CLINICAL CRITERIA IN LQT1 August 1998:486–91
sion and relative tachycardia may represent such other risk
factors predicting cardiac events. According to Zareba et al.
(13), heart rate .85 beats per minute in LQTS patients older
than 10 years is associated with increased risk of cardiac events,
but this may not be applicable to all forms of LQTS. The
clinical significance of the genetic disorder even without clin-
ically manifest disease may become evident, for example, when
a patient is exposed to QT interval prolonging drug. The
knowledge of the genetic status is thus important since it
enables patient counseling and avoidance of additional risk
factors even when he or she is an asymptomatic LQTS carrier.
Study limitations. There were certain limitations in the
present study. The study population consisted of patients with
one specific mutation of the KVLQT1 gene. In spite of its
critical location in the pore region of the potassium channel,
other mutations of the same gene may produce quantitatively
diverging alterations in repolarization phenomena. Therefore,
the distribution of QT intervals or dispersion parameters of
ventricular repolarization presented here cannot be general-
ized to all LQT1 patients without further studies.
Conclusions
Even in a genetically homogenous population, application
of electrocardiographic measures using the standard 12-lead
ECG only, or the clinical criteria, does not result in correct
diagnosis of all cases of LQTS. In addition to causing occa-
sional false negative diagnoses in clinical practice, we suspect
that some previous investigations may have the potential bias
of concentrating on the most aberrant patients only. QT
duration alone appears to be a poor predictor of cardiac events
even among patients possessing the same mutation. There is a
need to study the interplay between genetic and environmental
factors that modify the QT interval and the specific mutation
types in LQTS.
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